
States sue Trump, saying he is intimidating hospitals over gender-affirming care for youth
The complaint comes after a month in which at least eight major hospitals and hospital systems — all in states where the care is allowed under state law — announced they were stopping or restricting the care. The latest announcement came Thursday from UI Health in Chicago.
Trump's administration announced in July that it was sending subpoenas to providers and focusing on investigating them for fraud. It later boasted in a news release that hospitals are halting treatments.
The Democratic officials say Trump's policies are an attempt to impose a nationwide ban on the treatment for people under 19 — and that's unlawful because there's no federal statute that bans providing the care to minors. The suit was filed by attorneys general from 15 states and the District of Columbia, plus the governor of Pennsylvania, in U.S. District Court in Boston.
'The federal government is running a cruel and targeted harassment campaign against providers who offer lawful, lifesaving care to children,' New York Attorney General Letitia James said in a statement.
Trump and others who oppose the care say that it makes permanent changes that people who receive it could come to regret — and maintain that it's being driven by questionable science.
Since 2021, 28 states with Republican-controlled legislatures have adopted policies to ban or restrict gender-affirming care for minors. In June, the U.S. Supreme Court ruled that states have a right to enforce those laws.
For families with transgender children, the state laws and medical center policy changes have sparked urgent scrambles for treatment.
The medical centers are responding to political and legal pressure
The Center for Transyouth Health and Development at Children's Hospital Los Angeles, the biggest public provider of gender-affirming care for children in teens in the U.S., closed in July.
At least seven other major hospitals and health systems have made similar announcements, including Children's National in Washington D.C., UChicago Medicine and Yale New Haven Health.
Kaiser Permanente, which operates in California and several other states, said it would pause gender-affirming surgeries for those under 19 as of the end of August, but would continue hormone therapy.
Connecticut Children's Medical Center cited 'an increasingly complex and evolving landscape" for winding down care.
Other hospitals, including Penn State, had already made similar decisions since Trump returned to office in January.
Alex Sheldon, executive director of GLMA, an organization that advocates for health care equity for LGBTQ+ people, said the health systems have pulled back the services for legal reasons, not medical ones.
'Not once has a hospital said they are ending care because it is not medically sound,' Sheldon said.
Trump's administration has targeted the care in multiple ways
Trump devoted a lot of attention to transgender people in his campaign last year as part of a growing pushback from conservatives as transgender people have gained visibility and acceptance on some fronts. Trump criticized gender-affirming care, transgender women in women's sports, and transgender women's use of women's facilities such as restrooms.
On his inauguration day in January, Trump signed an executive order defining the sexes as only male and female for government purposes, setting the tone for a cascade of actions that affect transgender people. About a week later, Trump called to stop using federal money, including from Medicaid, for gender-affirming care for those under 19.
About half of U.S. adults approve of Trump's handling of transgender issues, an AP-NORC poll found. But the American Medical Association says that gender is on a spectrum, and the group opposes policies that restrict access to gender-affirming health care.
Gender-affirming care includes a range of medical and mental health services to support a person's gender identity, including when it's different from the sex they were assigned at birth. It includes counseling and treatment with medications that block puberty, and hormone therapy to produce physical changes, as well as surgery, which is rare for minors.
In March, a judge paused enforcement of the ban on government spending for care.
The court ruling didn't stop other federal government action
In April, Attorney General Pam Bondi directed government investigators to focus on providers who continue to offer gender-affirming care for transgender youth. 'Under my leadership, the Department of Justice will bring these practices to an end," she wrote.
In May, the Department of Health and Human Services issued a report discouraging medical interventions for transgender youth and instead focusing solely on talk therapy. The report questions adolescents' capacity to consent to life-changing treatments that could result in future infertility. The administration has not said who wrote the report, which has been deeply criticized by LGBTQ+ advocates.
In June, a Justice Department memo called for prioritizing civil investigations of those who provide the treatment.
In July, Justice Department announced it had sent more than 20 subpoenas to doctors and clinics involved in gender-affirming care for youth, saying they were part of investigations of health care fraud, false statements and other possible wrongdoing.
And in a statement last week, the White House celebrated decisions to end gender-affirming care, which it called a 'barbaric, pseudoscientific practice'
Families worry about accessing care
Kristen Salvatore's 15-year-old child started hormone therapy late last year at Penn State Health. Salvatore said in an interview with The Associated Press before the lawsuit was announced that it was a major factor in reduced signs of anxiety and depression. Last month, the family received official notice from the health system that it would no longer offer the hormones for patients under 19 after July 31, though talk therapy can continue.
Salvatore has been struggling to find a place that's not hours away from their Mechanicsburg, Pennsylvania, home that would provide the hormones and accept Medicaid coverage.
'I'm walking around blind with no guidance, and whatever breadcrumbs I was given are to a dead-end alleyway,' she said.
The family has enough testosterone stockpiled to last until January. But if they can't find a new provider by then, Salvatore's child could risk detransitioning, she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
an hour ago
- Reuters
Vertex's trial failure, scrapped study cloud pain drug push; shares slump
Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved pain drug, sending its shares down 14.4% after the bell. The company (VRTX.O), opens new tab has been diversifying into gene therapies and non-opioid painkillers as it looks to reduce its reliance on cystic fibrosis drugs, a market it dominates. Unlike opioids, which trigger the brain's reward centers, making them an addiction risk, Vertex's drugs block pain signals at the origin, providing a lucrative opportunity for the company. The next-generation non-opioid painkiller, called VX-993, reduced pain by 74.5 points over 48 hours, compared with 50.2 points in the placebo group, but the difference was not statistically significant, Vertex said. The company tested acute pain reduction in patients who had bunionectomy, a surgery to correct deformed bones of the big toe and foot. The drug was found to be generally safe, with most side effects being mild to moderate and no serious problems linked to the painkiller, the company said. Wall Street analysts and investors have been keenly watching the results of the trial, as Vertex seeks to expand beyond Journavx, its non-opioid approved by the U.S. Food and Drug Administration in January for acute pain. Separately, Vertex also said it would not start a study for Journavx to treat a type of nerve pain in the lower back and legs following discussion with the FDA. Leerink Partners analyst David Risinger said Vertex's pain portfolio updates were "disappointing," despite reporting second-quarter results that were above expectations. Vertex plans to prioritize testing of, and later seeking approval for, Journavx to treat a type of nerve pain in diabetic patients. It will also seek to secure approval for other types of nerve pain, the company said in its earnings press release.


The Independent
2 hours ago
- The Independent
Warning issued to patients after using weight-loss jabs
Health chiefs have raised concerns about patients regaining weight after stopping popular weight-loss drugs such as Wegovy and Mounjaro, calling for robust support to prevent them from piling on the pounds again. The National Institute for Health and Care Excellence (Nice), the UK's health watchdog, highlighted research indicating that many individuals regain weight if not adequately supported after ceasing treatment. Nice stressed that those coming off the drugs should be offered "structured advice and follow-up support" to mitigate weight gain. This guidance specifically applies to individuals receiving these treatments through the NHS. However, an estimated 1.5 million people in the UK are currently using weight-loss injections, with the vast majority paying privately. These individuals will not be eligible for NHS support once their treatment concludes. Over the next three years, approximately 240,000 people deemed to have the "greatest need" are anticipated to receive Mounjaro, also known as tirzepatide, via the NHS. The new 'quality standard' from Nice says that NHS patients should be monitored for at least a year after they complete treatment, and extra support should be offered if needed. It emphasises building 'long-term behavioural habits, use self-monitoring tools, and draw on wider support – from online communities to family-led interventions and local activities'. This standard, a type of guidance for the health services in England and Wales, sets out expectations for health providers including how they should support patients. 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme,' said Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Commenting, Henry Gregg, chief executive of the National Pharmacy Association, said: ' Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.' Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'There is no one-size-fits-all approach to tackling obesity – what works for one patient will likely not work for another and, as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. As such, this is important and sensible guidance from Nice. 'As a college, we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet' and ensuring access to sufficient 'wraparound' services – particularly for when patients come off their medication – will be key to optimal health outcomes.'


Daily Mail
2 hours ago
- Daily Mail
Wegovy and Mounjaro patients should be monitored for at least a YEAR after stopping drugs, watchdog says
Patients should be monitored for a year after stopping weight loss jabs to prevent them piling the pounds back on, new guidelines say. The drugs' watchdog is concerned about the number of people regaining weight after coming off the likes of Wegovy and Mounjaro. They must now be offered 'structured advice and follow-up support' to help them maintain healthy lifestyles for the long-term, the National Institute for Health and Care Excellence (Nice) said. Its guidance applies to everyone who obtains the treatments through the NHS in England and Wales - and healthcare workers are expected to comply immediately. An estimated 1.5 million people are taking weight loss jabs in the UK but the vast majority are paying around £200 a month to obtain them privately. Some 240,000 people with 'greatest need' are set to receive Mounjaro, also known as tirzepatide, through the NHS over the next three years. The new 'quality standard' from Nice tells health providers they should monitor NHS patients for at least a year after they complete treatment and offer extra tailored support if needed. It says: 'This could include practical advice from programmes like NHS Better Health on changing daily habits or making adjustments at home or work to avoid slipping back.' The guidance emphasises the need to establish 'long-term behavioural habits' and suggests the use of regular check-ins, community support groups, local activity classes, and help developing 'sustainable routines'. Studies found people injected with semaglutide, the active ingredient in Wegovy and Ozempic, lost 14 per cent of their body weight over 72 weeks. And those taking Mounjaro, known as the 'king kong' of weight-loss jabs, lost 20 per cent of their body weight over the the same period. But research also shows that many people regain weight after stopping treatment if they do not get the right help. Health officials say this can negatively affect their physical and mental health. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'Successful weight management doesn't end when medication stops or when someone completes a behavioural programme. 'We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they've made. 'This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a 'sickness service' to a genuine health service focused on prevention.' In England, 29 per cent of adults are obese and 64 per cent or overweight or obese. Obesity places extra pressure on the NHS and wider economy by increasing the risk type 2 diabetes, heart disease, cancer and musculoskeletal problems. Estimates suggest obesity costs the NHS £11.4 billion a year, with a wider economic impact of £74.3 billion due to lost productivity, unemployment and increased demand for social care. Dr Rebecca Payne, chair of Nice's Quality Standards Advisory Committee, added: 'Weight management is a long-term journey, not a short-term fix. 'The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits. 'We've seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. 'This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term. 'This standard ensures healthcare services are equipped to provide that essential ongoing support.' Professor Kamila Hawthorne, chair of the Royal College of GPs, said: 'There is no one-size fits all approach to tackling obesity - what works for one patient will likely not work for another, and as with any medication, weight-loss drugs do not come without risk. 'It's also the case that patients will likely need support to sustain their weight loss once they stop taking the medication. 'As such, this is important and sensible guidance from NICE. 'As a College we've been clear that whilst weight loss medications have significant potential benefits for patients who are struggling to lose weight, they mustn't be seen as a 'silver bullet', and ensuring access to sufficient 'wraparound" services – particularly for when patients come off their medication – will be key to optimal health outcomes. 'We need to see a greater focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.' Henry Gregg, chief executive of the National Pharmacy Association, said: 'Pharmacies take their responsibilities seriously to provide full wrap around support to patients trying to achieve a healthy weight. 'We know that although medication can be effective in speeding up weight loss in some people, it is not a silver bullet and patients need to make long term lifestyle changes to make their weight loss sustainable. 'The current NHS roll out of weight loss treatment is very small, with only a handful of patients receiving it and it will continue to be the case that the vast majority of eligible patients will be seen by their pharmacy.'